Both parties in CRISPR-Cas9 technology lawsuit can maintain patents, board rules

crispr_keegan_houser_ucberkeley_courtesy
Keegan Houser/UC Berkeley/Courtesy

The U.S. Patent Trial and Appeal Board ruled there was no interference between the patents requested by Broad Institute and the University of California regarding CRISPR technology, prompting the UC system to consider further legal steps to secure patent rights over the use of CRISPR-Cas9 in all types of cells and organisms.
Read More…